Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411


Share on StockTwits

Investor Ideas Potcasts #600: Cannabis news and stocks on the move - (CSE: BRAX) (OTC: BRAXF) (OTC: ERBB) (OTCQX: AVCNF) (NASDAQ: GNLN)

 

Delta, Kelowna, BC - August 27, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/082721-StocksToWatch.mp3

Investor Ideas Potcasts #600: (CSE: BRAX) (OTC: BRAXF) (OTC: ERBB) (OTCQX: AVCNF) (NASDAQ: GNLN)

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few public and private company announcements.

Greenlane Holdings, Inc. (NASDAQ: GNLN), a global house of brands and one of the largest sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, announced that its stockholders have approved the proposed merger with KushCo Holdings, Inc., a premier provider of ancillary products and services to the legal cannabis and CBD industries.

Over 99% of the votes cast on the merger proposal were voted in favor of the Transaction. Furthermore, each other proposal submitted to stockholders at Greenlane's annual meeting of stockholders was approved by the requisite vote. The Company expects to file with the Securities and Exchange Commission a Form 8-K disclosing the final voting results.

Pursuant to the terms of the merger agreement, KushCo will become a wholly owned subsidiary of Greenlane in an all-stock, tax-free business combination. Under the terms of the merger agreement, KushCo's stockholders will receive shares of Greenlane Class A common stock based on the final exchange ratio to be determined as of the closing date in accordance with the terms of the merger agreement.

Avicanna Inc. (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that, through its majority-owned Colombian subsidiary Santa Marta Golden Hemp S.A.S. ("SMGH"), it has completed its first commercial export of 20 kg of high CBD full spectrum psychoactive cannabis extracts (the "Cannabis Extracts") to Brazil in connection with the previously announced three (3) year master supply agreement that SMGH executed with a leading Brazilian pharmaceutical in July, 2021.

This marks the 11th country to which Avicanna has successfully completed export of Aureus-branded products in what stands as a demonstration of the Company's capabilities, innovation, and regulatory expertise. This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna's Aureus products offer.

With a forecasted total market size of approximately USD $9 billion by 2021, Brazil is expected to be one of the biggest cannabis markets globally and the largest in Latin America, particularly for medicinal cannabis products. The Cannabis Extracts will be used in the production of several products which will be registered and commercialized in Brazil through RDC 327/19 that regulates manufacturing, registration, importation and dispensing of cannabis-derived products.

Lucas Nosiglia, President of Avicanna LATAM, commented: "This export represents a key milestone for our team and a validation of our capabilities as we continue to lead the way with our products and have now entered our 11th country with the Aureus brand. The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners."

American Green (OTC: ERBB) announced that it will be expanding its E-commerce presence by launching on Groupon.com. American Green's premium CBD and Hemp products will be able to be purchased with vouchers located on the Groupon.com platform beginning next month (September 2021). The company is excited to add sales from Groupon as another revenue stream and hopes to echo or exceed the success it is currently enjoying following its launch on Amazon.com.

David G. Gwyther, American Green's president, said, "We are extremely excited to offer our CBD products on Groupon.com There are very few e-commerce outlets that sell CBD direct to consumers, and Groupon is by far the largest and most successful platform. Groupon has over 24 million customers nationwide. Consumers throughout the country will now have direct access to all of our CBD and Hemp products on Groupon.com."

"American Green is always looking for innovative ways to introduce its CBD and Hemp products to new prospects and new marketplaces. Groupon is perfectly aligned with our goals with respect to pioneering new ideas that drive rapid growth in e-commerce environments," said Kevin Davis, VP President of Sales for American Green.

The American Green offers will be optimized and marketed under Groupon's proprietary methods which include but are not limited to: flash sale offers, remarketing campaigns, utilization of additional channels (such as the Groupon app and partner websites) and other online advertising channels.

Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, announced that Braxia Scientific's clinical research and development team will commence a randomized clinical trial (RCT) using psilocybin.

"This will be the broadest study of its kind," said Dr. Joshua Rosenblat, the trial's principal investigator and medical director of the Canadian Rapid Treatment Centre of Excellence Inc. (CRTCE), a wholly owned subsidiary of Braxia Scientific.

"Whereas most other treatment-resistant depression (TRD) studies limit participation to patients that have not found relief from a maximum of five other potential remedies, our research will not have an upper limit, and will even include patients that have endured dozens of unsuccessful medical trials, including ketamine and electroconvulsive therapy.

"By including everyone with more than two failed medical trials, we are increasing the degree to which the results can be applied to a larger population, making our findings much stronger. Furthermore, we will have less exclusion criteria and are even including patients with bipolar depression - a huge first for the field - or comorbid disorders, which were excluded in psilocybin studies done by other companies."

Braxia Scientific CEO Dr. Roger McIntyre added, "Integrating psilocybin provides immense opportunity for benefit for those dealing with treatment-resistant depression. Unfortunately, over one-third of the more than 300 million people suffering with depression worldwide fail to adequately respond to currently approved treatments, and thus the TRD market is very large and disproportionately dominates the majority of mental health services."

The study will demonstrate that the Company can effectively conduct a randomized controlled trial using psychedelic-assisted therapy. This will enable the Company to build the infrastructure for future studies and future clinical care, while also compiling efficacy data and providing the opportunity to evaluate the therapist training program launched at the end of June 2021.

This program run by the Braxia Institute, the Company's training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy, has already cultivated a multi-disciplinary group of 20 therapists from diverse psychiatry and psychotherapy backgrounds to implement safe and effective psilocybin-assisted therapy for patients with depression.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea's original branded content includes podcasts and columns: Crypto Corner, Play by Play sports and stock news, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast, Cleantech and Climate Change, Exploring Mining, Betting on Gaming Stocks Podcast and the AI Eye Podcast.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com